Oculis Holding AG (NASDAQ:OCS – Get Free Report)’s stock price reached a new 52-week high during mid-day trading on Monday . The stock traded as high as $16.87 and last traded at $16.09, with a volume of 4021 shares traded. The stock had previously closed at $15.80.
Wall Street Analysts Forecast Growth
Separately, HC Wainwright reissued a “buy” rating and set a $30.00 target price on shares of Oculis in a research report on Wednesday, October 23rd. Five equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company currently has a consensus rating of “Buy” and an average target price of $29.20.
Oculis Trading Up 7.1 %
Oculis (NASDAQ:OCS – Get Free Report) last issued its quarterly earnings results on Tuesday, August 27th. The company reported ($0.56) EPS for the quarter, missing the consensus estimate of ($0.43) by ($0.13). Oculis had a negative return on equity of 61.33% and a negative net margin of 7,679.05%. The business had revenue of $0.27 million for the quarter, compared to analyst estimates of $0.28 million. On average, analysts predict that Oculis Holding AG will post -2.19 EPS for the current year.
About Oculis
Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis.
Featured Stories
- Five stocks we like better than Oculis
- Stock Market Holidays 2022-2025 – Here’s When the NYSE and NASDAQ Will be Closed
- 3 Oil Stocks to Watch Before Earnings Come Out
- What Are Dividends? Buy the Best Dividend Stocks
- Is American Express Stock’s Sell-the-News Reaction a Buying Opp?
- How to Use High Beta Stocks to Maximize Your Investing Profits
- Alphabet’s Earnings Could Surprise—Should You Buy Now?
Receive News & Ratings for Oculis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oculis and related companies with MarketBeat.com's FREE daily email newsletter.